A83-01

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:A-83-01 is an ALK inhibibitor. It was found that A-83-01 inhibited the transcriptional activity induced by TGF-beta type I receptor ALK-5 and that by activin type IB receptor ALK-4 and nodal type I receptor ALK-7, the kinase domains of which are structurally highly related to those of ALK-5. A-83-01 was found to be more potent in the inhibition of ALK5 than a previously described ALK-5 inhibitor, SB-431542, and also to prevent phosphorylation of Smad2/3 and the growth inhibition induced by TGF-beta. A-83-01 inhibited the epithelial-to-mesenchymal transition induced by TGF-beta, suggesting that A-83-01 and related molecules may be useful for preventing the progression of advanced cancers.

Price and Availability

A83-01, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 401002Name: A83-01CAS#: 909910-43-6Chemical Formula: C25H19N5SExact Mass: 421.13612Molecular Weight: 421.52Elemental Analysis: C, 71.23; H, 4.54; N, 16.61; S, 7.61

Synonym:A8301; A 8301; A-8301

IUPAC/Chemical Name:3-(6-methylpyridin-2-yl)-N-phenyl-4-(quinolin-4-yl)-1H-pyrazole-1-carbothioamide

InChi Key:HIJMSZGHKQPPJS-UHFFFAOYSA-N

InChi Code:InChI=1S/C25H19N5S/c1-17-8-7-13-23(27-17)24-21(19-14-15-26-22-12-6-5-11-20(19)22)16-30(29-24)25(31)28-18-9-3-2-4-10-18/h2-16H,1H3,(H,28,31)

SMILES Code:S=C(N1N=C(C2=NC(C)=CC=C2)C(C3=CC=NC4=CC=CC=C34)=C1)NC5=CC=CC=C5

Technical Data

Additional Information

References

1: Spinato S, Galindo-Moreno P, Zaffe D, BernardelloF, Soardi CM. Is socket healing conditioned by buccal plate thickness? Aclinical and histologic study 4 months after mineralized human boneallografting. Clin Oral Implants Res. 2012 Nov 21. doi:10.1111/clr.12073. [Epub ahead of print] PubMed PMID: 23167308.

2: Chen WP, Wu SM. Small molecule regulators of postnatal Nkx2.5cardiomyoblast proliferation and differentiation. J Cell Mol Med. 2012May;16(5):961-5. doi: 10.1111/j.1582-4934.2011.01513.x. PubMed PMID:22212626; PubMed Central PMCID: PMC3325363.

3: Shimada H, Hashimoto Y, Nakada A, Shigeno K, Nakamura T. Acceleratedgeneration of human induced pluripotent stem cells with retroviraltransduction and chemical inhibitors under physiological hypoxia.Biochem Biophys Res Commun. 2012 Jan 13;417(2):659-64. doi:10.1016/j.bbrc.2011.11.111. Epub 2011 Dec 8. PubMed PMID: 22172948.

4: Vogt J, Traynor R, Sapkota GP. The specificities of small moleculeinhibitors of the TGFß and BMP pathways. Cell Signal. 2011Nov;23(11):1831-42. doi: 10.1016/j.cellsig.2011.06.019. Epub 2011 Jun29. PubMed PMID: 21740966.

5: Yamamura S, Matsumura N, Mandai M, Huang Z, Oura T, Baba T, HamanishiJ, Yamaguchi K, Kang HS, Okamoto T, Abiko K, Mori S, Murphy SK, KonishiI. The activated transforming growth factor-beta signaling pathway inperitoneal metastases is a potential therapeutic target in ovariancancer. Int J Cancer. 2012 Jan 1;130(1):20-8. doi: 10.1002/ijc.25961.Epub 2011 Apr 18. PubMed PMID: 21503873.

6: Yuan X, Wan H, Zhao X, Zhu S, Zhou Q, Ding S. Brief report: combinedchemical treatment enables Oct4-induced reprogramming from mouseembryonic fibroblasts. Stem Cells. 2011 Mar;29(3):549-53. doi:10.1002/stem.594. PubMed PMID: 21425417.

7: Yu J, Chau KF, Vodyanik MA, Jiang J, Jiang Y. Efficient feeder-freeepisomal reprogramming with small molecules. PLoS One. 2011 Mar1;6(3):e17557. doi: 10.1371/journal.pone.0017557. PubMed PMID: 21390254;PubMed Central PMCID: PMC3046978.

8: Furutani Y, Umemoto T, Murakami M, Matsui T, Funaba M. Role ofendogenous TGF-β family in myogenic differentiation of C2C12 cells. JCell Biochem. 2011 Feb;112(2):614-24. doi: 10.1002/jcb.22953. PubMedPMID: 21268083.

9: Yuan X, Wan H, Zhao X, Zhu S, Zhou Q, Ding S. Combined ChemicalTreatment Enables Oct4-Induced Reprogramming from Mouse EmbryonicFibroblasts. Stem Cells. 2011 Jan 7. [Epub ahead of print] PubMed PMID:21218442.

10: Kawano K, Maitani Y. [Tumor permeability of nanocarriers observed bydynamic contrast-enhanced magnetic resonance imaging]. Yakugaku Zasshi.2010 Dec;130(12):1679-85. Review. Japanese. PubMed PMID: 21139395.

11: Taniguchi Y, Kawano K, Minowa T, Sugino T, Shimojo Y, Maitani Y.Enhanced antitumor efficacy of folate-linked liposomal doxorubicin withTGF-β type I receptor inhibitor. Cancer Sci. 2010 Oct;101(10):2207-13.doi: 10.1111/j.1349-7006.2010.01646.x. Epub 2010 Jul 1. PubMed PMID:20608940.

12: Minowa T, Kawano K, Kuribayashi H, Shiraishi K, Sugino T, Hattori Y,Yokoyama M, Maitani Y. Increase in tumour permeability followingTGF-beta type I receptor-inhibitor treatment observed by dynamiccontrast-enhanced MRI. Br J Cancer. 2009 Dec 1;101(11):1884-90. doi:10.1038/sj.bjc.6605367. Epub 2009 Nov 3. PubMed PMID: 19888220; PubMedCentral PMCID: PMC2788254.

13: Hoberg M, Rudert M, Pap T, Klein G, Gay S, Aicher WK. Attachment tolaminin-111 facilitates transforming growth factor beta-inducedexpression of matrix metalloproteinase-3 in synovial fibroblasts. AnnRheum Dis. 2007 Apr;66(4):446-51. Epub 2006 Nov 23. PubMed PMID:17124250; PubMed Central PMCID: PMC1856036.

14: Tojo M, Hamashima Y, Hanyu A, Kajimoto T, Saitoh M, Miyazono K, NodeM, Imamura T. The ALK-5 inhibitor A-83-01 inhibits Smad signaling andepithelial-to-mesenchymal transition by transforming growth factor-beta.Cancer Sci. 2005 Nov;96(11):791-800. PubMed PMID: 16271073.

MedKoo，由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区（ResearchTrianglePark,简称RTP)，是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司，该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司，高校，研究院所，政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。

中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸

MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务。

MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务和分子有竞争力的价格。MedKoo是您可靠的合作伙伴采购药物发现和药物分子。

MedKoo是世界的抗癌化学试剂和激酶抑制剂供应商之一。我们制造，销售和分销用于肿瘤学研究的高质量抗癌小分子试剂。我们的使命是建立世界上全面的抗癌小分子集合。我们还为制药行业，医学研究组织和学术机构提供高质量的研究服务。我们致力于以具有竞争力的价格提供服务和分子。MedKoo是您可靠的药物发现和药物分子采购合作伙伴。

CRISPR-Cas9是近年兴起的用于靶向基因组特定位置，进行DNA修饰的重要工具。研究发现CRISPR是细菌为了应对病毒的攻击而演化而来的获得性免疫防御机制。具体来说，在CRISPR和Cas9的作用下，经由小RNA分子的引导，靶向并沉默入侵者遗传物质核酸的关键部分。在该系统中，crRNA（CRISPR-derivedRNA）与tracrRNA（trans-activatingRNA）结合形成的复合物能特异性识别靶基因序列，并引导Cas9核酸内切酶在靶定位点剪切双链DNA，随后，细胞的非同源末端连接修复机制（NHEJ）重新连接断裂处的基因组DNA，并引入插入或缺失突变。另外也可以提供一个外源双链供体DNA（Donor）通过同源重组（HR）整合进断裂处的基因组，从而达到对基因组DNA进行修饰的目的。
目前，CRISPR-Cas9系统的高效基因组编辑功能已被应用于多种生物，包括小鼠、大鼠、斑马鱼、秀丽隐杆线虫，也包含多种细菌和植物，甚至在人体上也有应用。